The high recurrence of relapses in AML patients, attributed largely to the persistence and clonal evolution of leukemic stem cells, has long frustrated the medical community. Even intensive treatment is often ineffective, and high-risk and older patients are often ineligible for chemotherapy or hematopoietic stem cell transplants. These conditions have led to an urgent demand for new concepts in treating the disease. Today, drug developers are beginning to make progress with therapeutic options such as mutation-specific approaches to target molecularly defined subgroups.
Parexel is at the forefront of these advances, advising and conducting hundreds of trials per year, many with adaptive designs. We have developed strategies to deal with the need for rapid enrollment and treatment initiation required by the rapid progression of the disease.
Experience in the past 5 years in leukemia
+
clinical projects
+
sites
+